[HTML] cell.com

[HTML][HTML] Liver-targeted AAV8 gene therapy ameliorates skeletal and cardiovascular pathology in a mucopolysaccharidosis IVA murine model

K Sawamoto, S Karumuthil-Melethil, S Khan… - … therapy Methods & …, 2020 - cell.com
Mucopolysaccharidosis type IVA (MPS IVA) is due to the deficiency of GALNS (N-
acetylgalactosamine 6-sulfate sulfatase) and is characterized by systemic skeletal dysplasia …
被引用次数：24 相关文章

[引用][C] Liver-Targeted AAV8 Gene Therapy Ameliorates Skeletal and Cardiovascular Pathology in a Mucopolysaccharidosis IVA Murine Model

K Sawamoto, S Karumuthil-Melethil, S Khan… - … Therapy-Methods & …, 2020 - cir.nii.ac.jp
Liver-Targeted AAV8 Gene Therapy Ameliorates Skeletal and Cardiovascular Pathology in a
Mucopolysaccharidosis IVA Murine Model | CiNii Research CiNii 国立情報学研究所 学術情報 …
[HTML] sciencedirect.com

[HTML][HTML] Liver-Targeted AAV8 Gene Therapy Ameliorates Skeletal and Cardiovascular Pathology in a Mucopolysaccharidosis IVA Murine Model

K Sawamoto, S Karumuthil-Melethil, S Khan… - … Therapy-Methods & …, 2020 - Elsevier
Mucopolysaccharidosis type IVA (MPS IVA) is due to the deficiency of GALNS (N-
acetylgalactosamine 6-sulfate sulfatase) and is characterized by systemic skeletal dysplasia …
[HTML] nih.gov

[HTML][HTML] Liver-Targeted AAV8 Gene Therapy Ameliorates Skeletal and Cardiovascular Pathology in a Mucopolysaccharidosis IVA Murine Model

K Sawamoto, S Karumuthil-Melethil… - … Therapy. Methods & …, 2020 - ncbi.nlm.nih.gov
Abstract Mucopolysaccharidosis type IVA (MPS IVA) is due to the deficiency of GALNS (N-
acetylgalactosamine 6-sulfate sulfatase) and is characterized by systemic skeletal dysplasia …

Liver-Targeted AAV8 Gene Therapy Ameliorates Skeletal and Cardiovascular Pathology in a Mucopolysaccharidosis IVA Murine Model

K Sawamoto, S Karumuthil-Melethil… - Molecular …, 2020 - nemours.elsevierpure.com
Abstract Mucopolysaccharidosis type IVA (MPS IVA) is due to the deficiency of GALNS (N-
acetylgalactosamine 6-sulfate sulfatase) and is characterized by systemic skeletal dysplasia …

Liver-Targeted AAV8 Gene Therapy Ameliorates Skeletal and Cardiovascular Pathology in a Mucopolysaccharidosis IVA Murine Model

K Sawamoto, S Karumuthil-Melethil… - … therapy. Methods & …, 2020 - pubmed.ncbi.nlm.nih.gov
Mucopolysaccharidosis type IVA (MPS IVA) is due to the deficiency of GALNS (N-
acetylgalactosamine 6-sulfate sulfatase) and is characterized by systemic skeletal dysplasia …

Liver-Targeted AAV8 Gene Therapy Ameliorates Skeletal and Cardiovascular Pathology in a Mucopolysaccharidosis IVA Murine Model.

K Sawamoto, S Karumuthil-Melethil, S Khan… - … therapy. Methods & …, 2020 - europepmc.org
Abstract Mucopolysaccharidosis type IVA (MPS IVA) is due to the deficiency of GALNS (N-
acetylgalactosamine 6-sulfate sulfatase) and is characterized by systemic skeletal dysplasia …

Liver-Targeted AAV8 Gene Therapy Ameliorates Skeletal and Cardiovascular Pathology in a Mucopolysaccharidosis IVA Murine Model.

K Sawamoto, S Karumuthil-Melethil, S Khan… - … therapy. Methods & …, 2020 - europepmc.org
Abstract Mucopolysaccharidosis type IVA (MPS IVA) is due to the deficiency of GALNS (N-
acetylgalactosamine 6-sulfate sulfatase) and is characterized by systemic skeletal dysplasia …

Liver-Targeted AAV8 Gene Therapy Ameliorates Skeletal and Cardiovascular Pathology in a Mucopolysaccharidosis IVA Murine Model

K Sawamoto, S Karumuthil-Melethil… - Molecular …, 2020 - nemours.elsevierpure.com
Resumen Mucopolysaccharidosis type IVA (MPS IVA) is due to the deficiency of GALNS (N-
acetylgalactosamine 6-sulfate sulfatase) and is characterized by systemic skeletal dysplasia …